UK Top 10 News

Stay informed with the latest breaking news from across the UK

Lecanemab, a new Alzheimer’s drug developed by Eisai and Biogen, has shown promising results in UK clinical trials, slowing cognitive decline by 27% in early-stage patients over 18 months.
The drug, administered biweekly via infusion, targets amyloid plaques in the brain, a hallmark of Alzheimer’s.
Trials involving 1,800 UK patients demonstrated improved memory and thinking skills compared to placebos, raising hopes for the 900,000 UK dementia sufferers.
However, side effects like brain swelling and microbleeds affected 12% of participants, prompting caution.
The NHS is evaluating lecanemab’s cost-effectiveness, with annual costs estimated at £20,000 per patient, potentially straining budgets.
Alzheimer’s Research UK hailed the results as a breakthrough, but experts stress the need for early diagnosis to maximize benefits.
The drug awaits regulatory approval, with debates ongoing about accessibility and long-term efficacy.
2025-10-02 14:38:00



showbiz sport money travel garden news tech health science business politics culture environment